View Older Stories View More Recent Stories
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024
-
Superluminal Medicines Closes $120 Million Series A Round
-
Vesta Healthcare Raises $65 Million in Financing to Propel Growth
-
Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
-
Form SC 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Horizon Technology Finance (HRZN) Provides $35 Million Venture Loan Facility to Vesta Healthcare
-
Horizon Technology Finance Provides $35 Million Venture Loan Facility to Vesta Healthcare
-
Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
-
Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
-
Form SC 13G Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SC 13G/A AN2 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Form SC 13G Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
-
Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)
-
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
-
Dignify Therapeutics welcomes leading spinal injury expert Alexander "Sasha" Rabchevsky PhD, to its Scientific Advisory Board
-
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
-
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
-
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
-
Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias
-
Form SC 13D Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Magenta Medical Closes $105M Financing Led by Novo Holdings
-
Form SC 13G RECURSION PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Praxis Precision Medicin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
-
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
-
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
-
Form SC 13G Perceptive Capital Solut Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Evolent Health, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
-
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates
-
Form SC 13G BICYCLE THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B
-
Form SC 13G Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Structure Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela to Present Data Supporting Use of its Tissue-Agnostic MRD Assay for Recurrence Prediction and Monitoring in Patients with Head & Neck Cancer at the American Society of Clinical Oncology 2024
-
Gameto Raises $33 Million in Series B Financing to Advance Development and Commercialization of Novel Fertility Treatments
